Status:

COMPLETED

Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating

Lead Sponsor:

University Hospital, Ghent

Conditions:

Irritable Bowel Syndrome

Eligibility:

All Genders

18-75 years

Phase:

NA

Brief Summary

Intestinal microbiota dysbiosis is thought to play an important role in the complex pathophysiology of irritable bowel syndrome (IBS), especially in diarrhoea-predominant IBS and possibly in IBS with ...

Detailed Description

Intestinal microbiota dysbiosis is thought to play an important role in the complex pathophysiology of irritable bowel syndrome (IBS), especially in diarrhoea-predominant IBS and possibly in IBS with ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria for patients:
  • signed informed consent
  • Irritable bowel syndrome with predominant diarrhoea as defined by the ROME III criteria and with symptoms of abdominal bloating
  • IBS symptom score \> 3 on at least 2 subscores (abdominal discomfort, abdominal bloating, abdominal pain, urgency, stool frequency, stool consistency)
  • Exclusion Criteria for patients:
  • predominant constipation as defined by Rome III criteria
  • pregnancy or inadequate anti conception for the duration of the trial
  • celiac disease
  • any contra-indications for colonoscopy
  • structural abnormalities of the colon (e.g. ileocecal resection, gastric bypass)
  • severe gastro-intestinal comorbidities (e.g. IBD, coloncarcinoma)
  • non gastro-intestinal malignancy
  • severe psychiatric comorbidity which had important effects on the quality of life
  • antimicrobial treatment 4 weeks prior to screening visit
  • treatment with probiotics 2 weeks prior to screening visit
  • recent diagnosis of lactose intolerance (\< 3 months before screening visit)
  • any severe comorbidity that might interfere with the study course as determined by the treating physician
  • Inclusion criteria for donors
  • age 18 - 75 years
  • signed informed consent
  • normal screening protocol which includes screening for infectious diseases (eg. blood HIV, Syphilis, Hepatitis B or C; stool: enteropathogens, clostridium, ESBL, CPE)
  • Exclusion criteria for donors
  • presence of gastrointestinal symptoms
  • gastro-intestinal or other important comorbidity
  • obesity or metabolic syndrome
  • history of malignancy both gastrointestinal or systemic
  • presence of known colon polyps
  • recent placing of piercings/tattoos
  • sexual risk behaviour
  • antimicrobial therapy 3 months prior to donation

Exclusion

    Key Trial Info

    Start Date :

    October 1 2014

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2017

    Estimated Enrollment :

    64 Patients enrolled

    Trial Details

    Trial ID

    NCT02299973

    Start Date

    October 1 2014

    End Date

    December 1 2017

    Last Update

    December 8 2017

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Ghent University Hospital

    Ghent, Belgium, 9000